The presence of broadly neutralizing anti-SARS-CoV-2 RBD antibodies elicited by primary series and booster dose of COVID-19 vaccine.

In the latter two subgroups, higher rates of WT-neutralizing (25% for homogenous adenovirus-vectored subgroup, 36% for heterologous subgroup, 47% for mRNA subgroup, Chi-square, P = 0.3040) and cross-neutralizing (13% for homogenous adenovirus-vectored subgroup, 28% for heterologous subgroup, 17% for mRNA subgroup, Chi-square, P = 0.3447) antibodies were found in the anti-RBD B cell repertoire, but the difference did not reach statistical significance ( S2 Table and S2 Fig ).

also in 111,027 other papers